Cord Blood America Restructures Debt; Projects to be Cash Flow Positive
“The restructuring is a major step forward for Cord Blood America. With the signing of the agreement, Cord Blood America projects it will become cash flow positive for the first time in its history,” said
“We have emphasized to our shareholders that reducing debt is a major focus in 2009,” Mr. Schissler said. “This agreement provides us the opportunity to follow through on our commitment.” The Company recently announced that since the beginning of 2009, it has reduced long term debt by more than
“The storage of stem cells is a predictable, high margin revenue stream business with little bad debt,” Mr. Schissler continued. “The loan originally helped CBAI to acquire a large customer base with the CorCell acquisition, giving us consistent cash flow. The principals of Shelter Island Opportunity Fund worked with us to restructure our debt, putting us in position to run as a cash flow positive organization. This is a gesture of true partnering with CBAI, while sharing the stem cell vision to become a globally dominant stem cell storage company.”
Mr. Schissler also stressed that the entire stem cell sector and its investors await the announcement from the Obama Administration lifting the current ban on Federal funding for research on embryonic stem cell lines. “Continued progress and potential additional discoveries in the use of stem cells in treating diabetes, heart disease, and other major diseases will dramatically increase the number of families storing umbilical cord blood stem cells, the focus of our business,” Mr. Schissler said.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 firstname.lastname@example.org
SOURCE Cord Blood America, Inc.